v3.22.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Current assets:    
Cash $ 3,777,742 $ 4,823,745
Advances on research and development contract services 147,017 150,241
Prepaid insurance 130,101 109,029
Other prepaid expenses and current assets 51,919 10,249
Total current assets 4,106,779 5,093,264
Deferred offering costs 10,906
Total assets 4,117,685 5,093,264
Current liabilities:    
Accounts payable and accrued expenses, including $32,500 and $32,500 to related parties at March 31, 2022 and December 31, 2021, respectively 369,490 225,965
Research and development contract liabilities 275,103 76,961
Total current liabilities 644,593 302,926
Commitments and contingencies
Stockholders’ equity:    
Preferred Stock, $0.0001 par value; authorized – 10,000,000 shares; issued and outstanding – 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares – 729,167 shares 3,500,000 3,500,000
Common stock, $0.0001 par value; authorized – 100,000,000 shares; issued and outstanding – 13,746,593 shares 1,374 1,374
Additional paid-in capital 38,710,800 38,371,128
Accumulated deficit (38,739,082) (37,082,164)
Total stockholders’ equity 3,473,092 4,790,338
Total liabilities and stockholders’ equity $ 4,117,685 $ 5,093,264

Source